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Abstract
Background
Framingham risk equations are widely used to predict cardiovascular disease based on
health information from a single time point. Little is known regarding use of information from
repeat risk assessments and temporal change in estimated cardiovascular risk for predic-
tion of future cardiovascular events. This study was aimed to compare the discrimination
and risk reclassification of approaches using estimated cardiovascular risk at single and
repeat risk assessments
Methods
Using data on 12,197 individuals enrolled in EPIC-Norfolk cohort, with 12 years of follow-
up, we examined rates of cardiovascular events by levels of estimated absolute risk (Fra-
mingham risk score) at the first and second health examination four years later. We calcu-
lated the area under the receiver operating characteristic curve (aROC) and risk
reclassification, comparing approaches using information from single and repeat risk
assessments (i.e., estimated risk at different time points).
Results
The mean Framingham risk score increased from 15.5% to 17.5% over a mean of 3.7 years
from the first to second health examination. Individuals with high estimated risk (20%) at
both health examinations had considerably higher rates of cardiovascular events than
those who remained in the lowest risk category (<10%) in both health examinations (34.0
[95%CI 31.7–36.6] and 2.7 [2.2–3.3] per 1,000 person-years respectively). Using informa-
tion from the most up-to-date risk assessment resulted in a small non-significant change in
risk classification over the previous risk assessment (net reclassification improvement of
-4.8%, p>0.05). Using information from both risk assessments slightly improved
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discrimination compared to information from a single risk assessment (aROC 0.76 and 0.75
respectively, p<0.001).
Conclusions
Using information from repeat risk assessments over a period of four years modestly
improved prediction, compared to using data from a single risk assessment. However, this
approach did not improve risk classification.
Introduction
Quantitative assessment of cardiovascular risk forms part of strategies for prevention of cardio-
vascular disease (CVD) in many countries.[1,2] National guidelines suggest that multivariate
risk assessment tools, such as the Framingham equations, should be incorporated into a pro-
gramme of repeat risk assessment in order to identify individuals at high risk who could be tar-
geted for preventive interventions.[3–6]
Risk equations such as the Framingham risk score have been shown to predict cardiovascu-
lar disease over the short term reasonably accurately.[7,8] However, there is uncertainty about
their predictive ability over the longer term, with some studies suggesting significant predictive
discrepancy between short-term and lifetime risk.[9] This raises the possibility of false reassur-
ance in those with low short-term risk but high long-term risk. This concern might be
addressed by repeat assessments of short-term cardiovascular risk over time. However, there is
a lack of such evidence and the recent guideline by the American College of Cardiology Foun-
dation and American Heart Association stresses that research on the optimal timing to begin
risk assessment and repeat risk assessment in asymptomatic low-intermediate risk individuals
is needed.[10]
It is unclear whether information from repeat risk assessments (predicted risk at different
time points) or changes in predicted risk could improve the predictive ability of cardiovascular
risk scores above and beyond information obtained from a single risk assessment. The predic-
tive utility of a cardiovascular risk score could be influenced by changes in the distribution of
cardiovascular risk factors and their treatment over time, both within and between popula-
tions.[8,11] Although some studies have examined the predictive ability of selected cardiovas-
cular risk factors at different time points,[12] little evidence exists to document the overall
predictive ability of risk scores estimated at different time points.[13,14] The recent Editorial
by Gaziano andWilson stresses that the contribution to prediction of repeat risk assessment
using standard risk scores merits further study.[14]
We aimed to investigate the association between information from repeat risk assessment
(repeat values of the Framingham risk score and change in the score over time) with risk of car-
diovascular disease. We examined the added value of (i) repeat values of the Framingham risk
score at different time points and (ii) temporal change in the risk score, compared to the score
assessed at a single time point, for prediction of cardiovascular disease in a large British cohort.
Methods
Study design and population
We used data from the European Prospective Investigation for Cancer (EPIC)-Norfolk study, a
large prospective cohort.[15] Between 1993 and 1997, 25,639 men and women, aged 40–74
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years, attended a baseline health examination, which included a self-administered health and
lifestyle questionnaire, medical history taking, physical examination, and blood testing. Partici-
pants completed questionnaires about their personal and family history of disease, medication,
and lifestyle factors including diet, physical activity and smoking habits. They were asked
whether a physician had ever told them that they had any of the conditions in a list that
included diabetes, heart attack, and stroke. Anthropometric and blood pressure measurements,
and non-fasting blood samples were also taken at the health assessment. EPIC-Norfolk is simi-
lar to a nationally representative sample for anthropometric indices, blood pressure and serum
lipids, albeit with a lower prevalence of cigarette smoking.[15]
Participants were invited to attend a second health assessment after four years (1998–2001),
at which identical measurements were taken,[16] and 15,028 participants (59%) attended.
There was no formal quantitative cardiovascular risk assessment at either health examination.
We defined the second health examination as the point at which the most up-to-date risk
information was available (‘index’ assessment) and baseline health examination as providing
previously assessed risk information (‘prior’ assessment) (Fig 1). We limited our analysis to
individuals with complete data for calculating the Framingham risk score at the first and sec-
ond health examinations (n = 13,017). We excluded those with prior CVD at the first examina-
tion and those who developed a first CVD event up to the second health examination
Fig 1. Pictorial diagram of timeframe and information used for investigating the prediction of CVD events in this analysis. x = censored due to
diagnosis of cardiovascular disease: • = censored due to death from diseases other than cardiovascular disease.
doi:10.1371/journal.pone.0147417.g001
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(n = 820), leaving 12,197 individuals for our main analyses. Among these, 390 individuals were
prescribed lipid-lowering drugs at baseline or the second health examination. The study was
approved by the Norwich District Health Authority Ethics Committee. All participants gave
signed informed consent.
Assessment of cardiovascular risk
We used the most recent Framingham risk equations[17] to quantify the estimated 10-year
absolute cardiovascular risk for each individual at the first and second health examinations.
Variables used for calculating the Framingham risk score include age, sex, smoking status,
prevalent diabetes, use of anti-hypertensive drugs, systolic blood pressure, and total and HDL
cholesterol.
Follow-up and ascertainment of cardiovascular disease
We followed up participants who were free from cardiovascular disease at the time of their sec-
ond health examination for the development of a first CVD event or death. We report results
for follow-up from the second health examination to March 31st 2008, a median of 8.5 years
(interquartile range 7.9–9.3). Incident CVD was defined as a composite of fatal or non-fatal
cardiovascular disease, including hospitalisation from coronary heart disease and stroke, or
death from coronary heart disease, stroke and peripheral vascular disease. This was different
from the definition used in the original Framingham study which also includes less severe car-
diovascular events (coronary insufficiency, angina, transient ischemic attack, intermittent clau-
dication and heart failure). Vital status for all EPIC-Norfolk participants was obtained via
death certification at the Office for National Statistics. Participants admitted to a hospital were
identified by their National Health Service number. Hospitals were linked to the East Norfolk
Health Authority database, which identifies all hospital contacts throughout England and
Wales for Norfolk residents. Hospital record data and vital status information were complete
for 95% and 99% of participants respectively. Previous validation studies in this prospective
cohort indicated high specificity of such case ascertainment.[18]
Statistical analyses
We calculated the CVD event rates for groups characterised by (i) different magnitudes of
change in the Framingham risk score over time from the first to second health examination
and (ii) different levels of the Framingham risk score at the first and second health examina-
tions (absolute value cut-off:<10.0%, 10.0–19.9% and20%).
We compared the discrimination (the area under the receiver operating characteristic curve,
aROC), calibration (Hosmer-Lemeshow chi-square statistic), the goodness of fit after cox
regression (Gronnesby and Borgan test) and the global model fits (Bayesian information crite-
ria, BIC; and Akaike information criteria, AIC) between the Framingham risk score at the prior
and index health examinations (FRS1 and FRS2) and change in the risk score (deltaFRS) for
prediction of cardiovascular events.
To investigate the added value of using information from more than one risk assessment,
we developed two further Cox regression models (i) using the Framingham risk score at the
first health examination and change in the score between the first and second health examina-
tion as covariates (FRS1delta) and (ii) using the mean value of the Framingham risk score at
both health examinations as covariates (meanFRS). We then computed the measures of predic-
tive ability, as described above, comparing combined information from the two risk assess-
ments (the two new models: FRS21 and FRS2delta) with risk information from the single most
up-to-date or index risk assessment (i.e. the Framingham risk score at the second health
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examination, FRS2). The added value of risk scores computed at two different time points can
be seen as the added value of using risk estimates from a previous examination over and above
the current risk estimates or vise versa.
To determine the effect of increasing age on the CVD risk estimates and their ability to pre-
dict future CVD, we calculated a new FRS2 using risk factor values at the second health assess-
ment but age at the first health assessment, and compared its predictive ability with FRS1 and
FRS2 computed by a conventional method.
To determine whether the results differed by the length of time between the two risk assess-
ments, we compared the difference in the predictive ability (aROC) of the Framingham risk
score at a single time point (FRS2) and the use of the risk score from a previous examination in
addition to the most recent one (FRS21 or FRS2delta). We compared the predictive ability in
individuals whose time from the first to second health examination was below and above a
median value of 3.7 years.
To demonstrate the benefits of using estimated risk information from repeat risk assessment
in clinical practice, we calculated the net reclassification improvement (NRI) to determine
whether the most recent risk score (FRS2) helped improve risk classification by a previously
assessed risk score (FRS1).
We also performed a subgroup analysis in 11,807 individuals who were not prescribed lipid-
lowering drugs up to the time they attended the second health examination in order to examine
whether the main results would be influenced by the use of lipid-lowering drugs.
Results
Characteristics of participants by levels of absolute CVD risk estimated at the first health exam-
ination are shown in Table 1. The average 10-year absolute CVD risk increased over time
(from 15.5% to 17.5% over a median of 4 years from the prior to the index health examination,
p<0.001). Although an increase in absolute CVD risk over time was small, it was largely
explained by increasing age. After categorising participants into low, intermediate and high
risk at the two health examinations (estimated 10-year risk of<10.0%, 10.0–19.9% and
20.0% respectively), we found that two-thirds of the participants remained in the same risk
categories at the first and second health examinations.
Incidence of cardiovascular events
There were 1,371 cardiovascular events over 99,654 person-years of follow-up, an incidence of
13.8 per 1,000 person-years. Individuals with a higher estimated absolute risk at baseline had a
higher incidence rate of cardiovascular events than those with a lower estimated absolute risk.
This was also observed for the second health examination. Individuals who had a small change
in their estimated cardiovascular risk (< 5%) over time had a low incidence of cardiovascular
events in the eight following years (9.8, 95% confidence interval 9.1–10.6 per 1,000 person-
years). Those with a big change in their estimated cardiovascular risk (5%), either negative or
positive change, had significantly high incidence rate of cardiovascular events (21.3; 95%CI
19.4–23.3 and 30.0; 95% CI 26.5–34.7 per 1,000 person-years for those with increased and
decreased risk of5%, respectively).
Individuals with high estimated risk at both health examinations had a higher cardiovascu-
lar event rate than those with high estimated risk at only one of the two health examinations
(Fig 2). Those with high estimated risk at either health examination had considerably higher
rates of cardiovascular events than those who remained in the lowest risk category at both
health examinations.
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Prediction of cardiovascular events
The Framingham risk score estimated at the first health examination (FRS1) was slightly better
than the score estimated at the second health examination (FRS2) at discriminating between
individuals who developed cardiovascular events and those who did not (aROC 0.76 (95%CI
0.75–0.77) and 0.75 (95%CI 0.74–0.76) respectively, p = 0.008), while change in the score over
3.7 years (deltaFRS) provided poor discrimination (aROC 0.53; 95%CI 0.51–0.55) (Table 2).
The Framingham risk score at either health examination (FRS1 or FRS2) showed a slightly bet-
ter model fit than the temporal change risk score. The Framingham risk score was poorly cali-
brated in the EPIC-Norfolk cohort at both health examinations e.g. cardiovascular risk was
over-estimated by 38% and 56% for prior and index health examination respectively.
Added value of repeat cardiovascular risk assessment
Using estimated absolute risk information from both health examinations (FRS1delta and
meanFRS) slightly improved the discriminatory ability of risk information from a single risk
Table 1. Characteristics of EPIC-Norfolk participants included in this analysis by levels of estimated 10-year absolute cardiovascular risk, the Fra-
mingham risk score (FRS), at the baseline health examination (n = 12,197).
Total Estimated 10-year absolute cardiovascular risk at
baseline
p-value *
<10.0% 10.0–19.9% 20.0%
Number 12,197 5,249 3,655 3,293
Age, years 58.0 (8.9) 52.0 (6.7) 59.8 (7.4) 65.8 (6.3) <0.001
Male sex 5,151 (42.2) 1,040 (19.8) 1,688 (46.2) 2,423 (73.6) <0.001
Social class I-IIIa † 7,641 (62.6) 3,371 (64.2) 2,281 (62.4) 1,989 (60.4) 0.002
Current smokers 1,110 (9.1) 315 (6.0) 298 (8.2) 497 (15.1) <0.001
Family history of cardiovascular disease‡ 6,288 (51.6) 2,475 (47.2) 1,990 (54.4) 1,823 (55.4) <0.001
Body mass index, kg/m2 25.9 (3.6) 25.0 (3.6) 26.3 (3.6) 26.8 (3.4) <0.001
Obesity (body mass index 30 kg/m2) 1,477 (12.1) 472 (9.0) 504 (13.8) 508 (15.4) <0.001
Systolic BP, mmHg 133.8 (17.6) 123.1 (12.8) 136.6 (13.9) 147.9 (16.9) <0.001
Total cholesterol, mmol/l 6.1 (1.1) 5.7 (1.0) 6.3 (1.1) 6.5 (1.2) <0.001
HDL cholesterol, mmol/l 1.4 (0.4) 1.6 (0.4) 1.4 (0.4) 1.2 (0.3) <0.001
Triglyceride, mmol/l 1.5 (1.0–2.1) 1.1 (0.8–1.6) 1.6 (1.2–2.2) 1.9 (1.4–2.6) <0.001
HbA1c, %
§ 5.3 (0.7) 5.1 (0.6) 5.3 (0.7) 5.6 (1.0) <0.001
Diabetes ¶ 364 (3.0) 37 (0.7) 71 (1.9) 256 (7.8) <0.001
Use of anti-hypertensive drugs 1,691 (13.9) 256 (4.9) 478 (13.1) 957 (29.1) <0.001
Use of lipid-lowering drugs 122 (1.0) 29 (0.6) 51 (1.4) 42 (1.3) <0.001
FRS at baseline, % over 10 years 11.8 (6.0–21.0) 5.6 (3.7–7.7) 14.1 (11.9–16.7) 29.3 (24.0–37.7) <0.001
FRS at 2nd health examination, % over 10 years 13.5 (7.3–23.9) 6.7 (4.4–9.6) 16.2 (12.6–20.8) 31.7 (24.5–41.6) <0.001
Data are presented in number (%), mean (standard deviation) and median (interquartile range) for categorical, normally and non-normally distributed
continuous variables respectively.
* differences between groups using x2 tests for categorical variables, and analysis of variance (ANOVA) or Kruskal-Wallis tests for normally or non-
normally distributed continuous variables.
† Registrar General's Social Class: class I = Professional, etc. occupations, II = Managerial and Technical occupations, IIIa = Skilled occupations (non-
manual), IIIb = Skilled occupations (manual), IV = Partly-skilled occupations, V = Unskilled occupations.
‡ Family history of cardiovascular disease deﬁned as a history of cardiovascular disease in ﬁrst degree relatives.
§ data for only 5,648 individuals with HbA1c
¶ Diabetes deﬁned as self-report of physician diagnosed diabetes and/or HbA1c at ﬁrst health examination of 6.5%.
doi:10.1371/journal.pone.0147417.t001
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Fig 2. Rates of a first cardiovascular events by levels of estimated absolute risk at the first (FRS1) and second health examination four years later
(FRS2). Note: The line above each bar indicates the 95% confidence interval, and the number above each bar represents the number of participants in each
risk category.
doi:10.1371/journal.pone.0147417.g002
Table 2. Comparisons between the risk scores at different health examinations of the measures of predictive ability for a first cardiovascular
event in the EPIC-Norfolk cohort (n = 12,197).
FRS1 FRS2 deltaFRS FRS1delta meanFRS
aROC 0.761 (0.749–0.774) 0.752 (0.739–0.764) 0.528 (0.509–0.547) 0.764 (0.739–0.764) 0.763 (0.751–0.775)
Observed events 1,371 1,371 N/A N/A N/A
Predicted events 1,891 2,134 N/A N/A N/A
Hosmer-Lemeshow Chi-square statistic 103.6 (p<0.001) 104.0 (p<0.001) N/A N/A N/A
Gronnesby and Borgan test 211.8 (p<0.001) 186.0 (p<0.001) N/A N/A N/A
AIC* 23,972 24,054 24,803 23,953 23,962
BIC* 23,980 24,061 24,811 23,968 23,969
Abbreviation: FRS1 = Framingham risk score at the ﬁrst health examination, FRS2 Framingham risk score at the second health examination,
deltaFRS = change in the Framingham risk score from baseline to the second health examination, FRS1delta = combination of the Framingham risk score
at the ﬁrst health examination and change in the score between the ﬁrst and second health examination, meanFRS = mean value of the Framingham risk
scores from both the ﬁrst and second health examinations, AIC = Akaike information criteria, and BIC = Bayesian information criteria
* lower values of the AIC and BIC suggest a better model ﬁt.
doi:10.1371/journal.pone.0147417.t002
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assessment (FRS2) (Table 2: aROC 0.76, 0.76 and 0.75 respectively, p<0.001), with a slightly
better global model fit.
When replacing age at the second health assessment with age at the first health assessment
in the Cox model at the second health assessment, the estimated CVD risk reduced signifi-
cantly from 17.5% to 15.3% and its predictive ability did not differ from FRS1.
As shown in Table 3, among 1,371 individuals who developed a first CVD event, using
information from the most recent risk assessment (FRS2) resulted in a net gain in reclassifica-
tion of 7.5%, compared to using information from a previous risk assessment (FRS1). In 10,826
individuals who did not experience a CVD event, using information from the most recent risk
assessment (FRS2) worsened classification, with a net decline in reclassification of 12.3% com-
pared to using information from the previous risk assessment (FRS1). Therefore, the overall
NRI for using information from the most up-to-date risk assessment over that from the previ-
ous risk assessment was estimated to be -4.8% (p = 0.99).
Larger differences in the predictive ability of the Framingham risk score at a single time
point (FRS2) and use of risk scores from previous examination in addition to the most recent
one (FRS21 or FRS2delta) were observed for participants with a longer period from the first to
second health examination (time period< 3.7 years, aROC for FRS2 and FRS21 0.77 and 0.78
respectively, X2 = 6.40, p = 0.011; corresponding estimates for time period3.7 years, 0.73 and
0.75, X2 = 21.37, p<0.001).
In a subgroup analysis in 11,807 individuals who were not prescribed lipid-lowering drugs,
we found similar results e.g. using information from repeat risk assessments modestly
improved the predictive ability of information from a single risk assessment.
Discussion
Using data from a large population-based prospective cohort with repeat health examinations,
we estimated the predictive ability of approaches for estimating risk using information from a
Table 3. Cardiovascular disease risk classification comparing the Framingham risk score at baseline with the Framingham risk score at the sec-
ond health examination in the EPIC-Norfolk cohort (n = 12,197).
Individuals who developed cardiovascular events
Framingham risk score at the 2nd health examination
< 10.0% 10.0–19.9%  20.0%
Framingham risk score at baseline Total
< 10.0% 95 57 2 154
10.0–19.9% 30 230 145 405
 20.0% 3 68 741 812
Total 128 355 888 1,371
Individuals who did not develop cardiovascular events
Framingham risk score at the 2nd health examination
< 10.0% 10.0–19.9%  20.0%
Framingham risk score at baseline Total
< 10.0% 3,994 1,060 41 5,095
10.0–19.9% 330 2,034 886 3,250
 20.0% 13 312 2,156 2,481
Total 4,337 3,406 3,083 10,826
Note: The net reclassiﬁcation improvement was 4.8%, p = 0.99
doi:10.1371/journal.pone.0147417.t003
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single contemporary risk assessment and incorporation of risk information collected previ-
ously. Compared to risk information from a single risk assessment, using information from
repeat risk assessments over a period of 4 years slightly improved discrimination but did not
improve risk classification.
Comparison with previous studies
Limited evidence exists concerning the optimal frequency of risk assessment in asymptomatic
individuals. The National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP
III) guideline states that the Framingham equations are not intended to be used to track
changes in risk over time as risk factors are modified as a result of treatment.[5] The NCE-
P-ATP III, however, suggests measuring lipid profiles at least once every 5 years in low risk
adults aged20 years old, but does not provide any clear guidance on how often cardiovascu-
lar risk measured by the Framingham equations should be reassessed in apparently healthy
individuals who do not receive intensive treatments. The European cardiovascular societies[6]
and Joint British Societies[4] guidelines suggest that global risk assessment be repeat every 5
years, without citing any supporting evidence. The recent guideline by the American College of
Cardiology Foundation and American Heart Association stresses that research on the optimal
timing to begin risk assessment and repeat risk assessment in asymptomatic low-intermediate
risk individuals is needed.[10]
Using data from the Framingham Heart Study with repeat risk factor measurements, Karp
et al found that the predictive ability of the multivariate risk score estimated using updated
data was better than the score estimated previously.[13] They also suggested that the optimal
frequency of updating cardiovascular risk information may vary across subpopulations with
different ages and sexes, and that updating risk information every two years may not be prefer-
able to updating every six years. However, the authors only examined the discriminatory ability
of the models. Our study examined the NRI of different models, which is useful in terms of
reclassification of individuals who would develop future cardiovascular events.[14]
A modelling study commissioned by the UK Department of Health (DH) suggested that
cardiovascular risk assessment based on the Framingham risk equations or similar tools should
be repeated every 5 years in individuals aged 40–74 years. The authors concluded that when
followed by appropriate preventive interventions, the risk assessment programme is likely to
be cost-effective compared to no screening, and to have the highest net benefits compared to
other screening strategies.[19] The authors accounted for changes in levels of risk factors and
cardiovascular risk over time in their model.[20] However, they assumed no change in choles-
terol over time, that nobody would take up smoking if they did not smoke already and that
those who had quit smoking for more than 12 months would not start smoking again. The
authors also assumed that a proportion of the population would become hypertensive each
year, while blood pressure would be stable among the remainder of the population.[20] Given
these limitations, there is continuing uncertainty over recommendations for optimal frequency
for cardiovascular risk assessment.
Of note, only a small number of participants were on lipid lowering drugs either at first or
second health examination (1993–2001). This might be explained by that the majority of
EPIC-Norfolk participants were generally apparently healthy at the time of recruitment. Also,
as landmark large-scale trials on benefits of statins on primary and secondary prevention of
cardiovascular disease were published in mid-late 1990s (e.g. 4S, LIPID, AFCAPS/TexCAPS,
HPS), the use of lipid lowering drugs, particularly statins for primary prevention, was expect-
edly low by 1997 and probably was slowly increasing during 1998–2001 before the concept of
primary prevention of CVD through use of statins was widely accepted.
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Policy implications
Our findings suggest that repeating risk assessments within a period of 4 years modestly
improve prediction compared with a single risk assessment. Indeed, using information from
repeat risk assessments over such a relatively short time does not seem to accurately reclassify
people into appropriate risk categories. A sensitivity analysis examining the predictive ability
of the risk score calculated by keeping age constant suggests that changes in CVD risk factors
over a short period of four years may contribute little to changes in estimated CVD risk and
added predictive values. Accordingly, our findings do not suggest that a new CVD risk assess-
ment is needed to be done, at least within a period of four years. However, our stratified analy-
sis suggests that repeat risk assessment over a longer period may improve the incremental
predictive ability over a single risk assessment to a greater extent than repeating assessment
over a shorter period. Therefore, value of repeating risk assessment over a longer period of
time remains uncertain and merits further investigation. Of note, our analysis was concerned
with effects of repeat assessment on prediction of cardiovascular disease. Further research is
therefore needed to investigate how often the assessment of individuals’ short-term cardiovas-
cular risk should be repeated to optimise population risk stratification and the delivery of
scarce preventive treatment resources to those with most to gain.
Some investigators proposed the use of lifetime risk for cardiovascular disease in conjunc-
tion with a shorter-term 10-year risk,[9,21–23] as there is a significant discrepancy between the
levels of short-term and lifetime risk.[9,23] This is particularly pronounced in young and mid-
dle-aged men who had a low short-term risk, but a high lifetime risk. Stratifying a population
using information only on short-term risk may overlook a significant number of people with
high lifetime risk, who might benefit from preventive interventions.[9,22] There is also evi-
dence that information on high lifetime risk might lead to more intensive prescription of aspi-
rin or lipid-lowering drugs by primary care physicians.[24] However, there remains
uncertainty over the role of lifetime risk estimation in individualised risk management.[25] In
deed, it remains unclear whether clinicians should prescribe lipid lowering drugs in those with
a low short-term but high lifetime estimated risk. It is unclear if it is more cost-effective to start
prescribing lipid-lowering drugs to young adults, who are unlikely to develop cardiovascular
disease within the short term, in order to prevent cardiovascular events in the longer term, or
to repeat assessments of short-term risk over time and to prescribe treatment when the short-
term risk is beyond a 20% risk threshold.[23]
Strengths and limitations
To our knowledge, our study is the first to investigate the potential use of information from
repeat risk assessment over time for prediction and reclassification of cardiovascular risk. We
used information on risk factors from repeat health examinations to calculate widely used mea-
sures of predictive ability and reclassification for the development of cardiovascular events
over a 9-year follow-up period However, four years may not have been sufficiently long to
exclude the possibility that repeat risk assessment has some merit. Further research is needed
to investigate the impact of approaches using repeat risk assessment over a longer period, e.g.
10 years, on cardiovascular risk prediction and classification in a general population, as well as
complementary strategies to improve risk stratification, e.g. a stepwise approach including
both short-term and long-term risk.
Our findings should be interpreted in the light of a number of limitations. Due to our
research question, we excluded those who did not have information on the second health
examination. Those who attended the follow-up examination were healthier than those who
did not (according to their baseline risk factor profiles), which might have led to an
Repeat Risk Assessment Adds Little to Prediction
PLOS ONE | DOI:10.1371/journal.pone.0147417 February 19, 2016 10 / 12
underestimation of cardiovascular event rates in the whole cohort. However, it is not clear how
this may have influenced the predictive ability and reclassification of approaches using infor-
mation from repeat risk assessments. As only 25% of the cohort were followed from the second
health examination for up to 10 years, the incidence of CVD events of the whole cohort may be
low. This might have altered the discrimination and calibration of the risk equations in this
analysis.
Using hospital linkage data for the ascertainment of CVD outcomes might lead to misclassi-
fication of non-fatal CVD events, as not all non-fatal CVD cases lead to hospital admission.
However, this method captures the nonfatal events of most clinical importance, and previous
validation studies in this cohort indicated high specificity of such case ascertainment.[18]
Additionally, as the definitions of cardiovascular events used in the present study and the Fra-
mingham study are different, this might have altered the predictive ability of the risk scores.
Lastly, as the majority of EPIC-Norfolk participants are of European descent, the generalisabil-
ity of our findings to other ethnic groups and populations is limited.
Conclusions
Compared to a single cardiovascular risk assessment, information on repeat risk assessments
over 4 years may slightly improve the ability to discriminate individuals according to their car-
diovascular risk. However, such an approach does not improve risk reclassification in this Brit-
ish population. Further research is needed to investigate the potential benefits and costs of
different frequencies of cardiovascular risk assessment, e.g. 10 years vs. lifetime horizon, and to
explore effects of risk assessment and communication on patient and practitioner behaviour.
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